PDE4B-IN-3

• CAT Number: I043504
• CAS Number: 2819779-01-4
• Molecular Formula: C30H35N3O4S2
• Molecular Weight: 565.75
• Purity: ≥95%
• Synonyms: N-[3-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]phenyl]quinoline-8-sulfonamide
• InChI: InChI=1S/C30H35N3O4S2/c1-19(2)23-16-26(20(3)4)30(27(17-23)21(5)6)39(36,37)33-25-13-8-12-24(18-25)32-38(34,35)28-14-7-10-22-11-9-15-31-29(22)28/h7-21,32-33H,1-6H3
• InChIKey: KNCHLPMJSHBPHC-UHFFFAOYSA-N
• SMILES: CC(C)C1=CC(=C(C(=C1)C(C)C)S(=O)(=O)NC2=CC=CC(=C2)NS(=O)(=O)C3=CC=CC4=C3N=CC=C4)C(C)C

PDE4B-IN-3 is a potent PDE4B inhibitor with an IC50 of 0.94 μM. PDE4B-IN-3 has anti-inflammatory activities[1].
PDE4B-IN-3 (compound f4) has good inhibitory activity on the production of NO, TNF-α and IL-1β with IC50 values of 20.40 μM, 23.48 μM, and 18.98 μM in RAW264.7 cells. PDE4B-IN-3 could also inhibit the expression of iNOS and COX-2 in RAW264.7 cells[1].
In vivo studies shows that PDE4B-IN-3 (compound f4; 10-30 mg/kg) could improve the degree of foot swelling and knee joint pathology in adjuvant-induced arthritic rats and decrease the levels of serum inflammatory factors TNF-α and IL-1β in a dose-dependent manner[1].

Reference

[1]. Siqi Xing, et al. Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis. Eur J Med Chem. 2022 Aug 5;238:114497.
 [Content Brief]